2023
DOI: 10.3390/ijms24032111
|View full text |Cite
|
Sign up to set email alerts
|

Natural Killer Cell-Based Immunotherapy against Glioblastoma

Abstract: Glioblastoma (GBM) is the most aggressive and malignant primary brain tumor in adults. Despite multimodality treatment involving surgical resection, radiation therapy, chemotherapy, and tumor-treating fields, the median overall survival (OS) after diagnosis is approximately 2 years and the 5-year OS is poor. Considering the poor prognosis, novel treatment strategies are needed, such as immunotherapies, which include chimeric antigen receptor T-cell therapy, immune checkpoint inhibitors, vaccine therapy, and on… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
8
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
7
1
1

Relationship

2
7

Authors

Journals

citations
Cited by 18 publications
(8 citation statements)
references
References 213 publications
0
8
0
Order By: Relevance
“…Previous studies have demonstrated that patients with glioma exhibit limited sensitivity to immunotherapy ( Yu and Quail, 2021 ). However, the identification of advanced immunotherapy regimens ( Luo et al, 2023 ; Morimoto et al, 2023 ), and emerging treatment targets ( Zhuo et al, 2023 ) is anticipated to overcome this obstacle. Upon examining the three cohorts, we observed that patients with an elevated IGF1RS exhibited a heightened response to anti-PD1 treatment.…”
Section: Discussionmentioning
confidence: 99%
“…Previous studies have demonstrated that patients with glioma exhibit limited sensitivity to immunotherapy ( Yu and Quail, 2021 ). However, the identification of advanced immunotherapy regimens ( Luo et al, 2023 ; Morimoto et al, 2023 ), and emerging treatment targets ( Zhuo et al, 2023 ) is anticipated to overcome this obstacle. Upon examining the three cohorts, we observed that patients with an elevated IGF1RS exhibited a heightened response to anti-PD1 treatment.…”
Section: Discussionmentioning
confidence: 99%
“…However, the interaction between MHC-I and killer cell immunoglobulin-like receptors can inhibit NK cell function, leading to reduced destruction of healthy cells [ 823 , 824 ]. Due to these advantageous properties, numerous preclinical and clinical trials have explored the effectiveness of CAR NK-cell-based immunotherapy against GB, utilizing NK cells as either autologous or allogeneic therapy [ 825 ]. Allogeneic NK cells offer potential benefits for immune-suppressed patients as they exhibit greater anti-tumor capabilities against GB when compared to exhausted NK cells derived from patients’ peripheral blood mononuclear cells [ 826 ].…”
Section: Immunotherapiesmentioning
confidence: 99%
“…Different approaches utilizing CAR NK-cell therapy include adoptive NK cell therapy (autologous and allogeneic therapy which implies obtaining the patient’s cells and tissues, expanding them ex vivo, and re-infusing them back into the patient), CAR-NK cell therapy (using NK cells engineered to express activating CARs), checkpoint blockade therapy (e.g., combination therapy of NK cells activated by IL-2 and TDK derived from HSP70, and anti-PD1 antibody), and gene editing NK therapy (e.g., the CRISPR/Cas9 genetic-editing system widely utilized to genome-edit T cells to disrupt inhibitory genes such as PD1 and CTLA4) (see [ 825 ] for a recent review). CAR-NK cells have advantages in safety profile compared with CAR-T cells, including reduced risk of graft-versus-host disease, cytokine release syndrome, and neurotoxicity [ 827 ].…”
Section: Immunotherapiesmentioning
confidence: 99%
“…Although there have been several studies on GBM immunotherapies, few effective strategies were discovered [ 9 , 10 ]. Given their high cytotoxicity and T cell receptor/human leucocyte antigen (HLA)-unrestricted effector function, natural killer cells (NKCs) have become an encouraging alternative platform for T cell-based immunotherapy platform [ 11 ]. Immunotherapy based on NKCs exemplifies a cancer therapeutic approach that is unlike T cell-based therapies.…”
Section: Introductionmentioning
confidence: 99%